Combination therapy against anti-PD-1-resistant lung cancer. A combination of...
Combination therapy against anti-PD-1-resistant lung cancer. A combination of anti-PD-1 antibodies and stimulator of an interferon gene (STING)-loaded lipid nanoparticles (STING-LNP) had the maximum effect in reducing metastases (black regions) on lungs (pink tissue; far right). STING-lipid nanoparticles alone had a better effect (center right) than anti-PD-1 antibodies (center left), which were as effective as the control saline solution.

Image source: Nakamura et al., Journal for ImmunoTherapy 2021 (CC BY-NC 4.0)

News • Promising approach

New nanoparticles suppress resistance to cancer immunotherapy

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to an immunotherapy treatment for cancer.

The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.

Photo
After intravenous injection into mice, STING-lipid nanoparticles (red) transported through blood vessels (green) accumulate in the liver

Image source: Nakamura et al., Journal for ImmunoTherapy 2021 (CC BY-NC 4.0)

The activation of checkpoint proteins on the surfaces of immune cells help regulate the immune response by preventing them from indiscriminately attacking the body’s other cells. But some cancer cells are able to hijack this mechanism, preventing an immune response against them as well. Scientists have recently developed immune checkpoint inhibitors that can counteract this strategy, but some people are resistant to the treatments. Now, scientists at Hokkaido University and Aichi Institute of Technology have found a way around this by developing a specially designed lipid nanoparticle that can carry immunity-triggering molecules into immune cells in the liver called macrophages.

The lipid, called YSK12-C4, has a high affinity for immune cells. When intravenously injected into mice with metastatic melanoma, it was able to deliver signaling molecules, called cyclic dinucleotides, across the cell membranes of their liver macrophages, where they stimulated the production of immune-related proteins called type 1 interferons via a stimulator of an interferon gene (STING) pathway. These were released into the blood, activating another type of immune cell called natural killer cells in the spleen and lung, which produced interferon-gamma inside the lung metastases.

portrait of takashi nakamura
Takashi Nakamura, lead author of this study

Image source: Hokkaido University; Photo: Takashi Nakamura

This treatment, on its own, only elicited a mild anti-tumor effect. This is because the type 1 interferons and interferon-gamma triggered the expression of a protein called PD-L1 on the cancer cells. PD-L1 prevents a strong tumor-killing immune response of natural killer cells that express PD-1. Administering an anti-PD-1 immunotherapy treatment, however, prevented the cancer cells from turning off those natural killer cells, which then became armed and able to launch a full-scale attack.

“The findings suggest that our lipid nanoparticles carrying immune-signaling molecules convert the immune status from immunologically cold to immunologically hot,” says Takashi Nakamura of Hokkaido University’s faculty of pharmaceutical sciences. “This could lead to the development of a promising adjuvant that reduces resistance to anti-PD-1 antibody treatment in some cancer patients.” Further studies will need to examine whether the treatment can cause liver toxicity and if different signaling molecules can be used.


Source: Hokkaido University

19.09.2021

Read all latest stories

Related articles

Photo

News • Detecting tumors and metastases

Nanoparticles deliver double strike against cancer

A new nanocomplex renders a tumor harmless – and, on top of that, it trains the immune system to detect and eliminate metastases.

Photo

News • Astrocyte research

New insight into how cancer metastasizes to the brain

A new US-led study shows that astrocyte brain cells play an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells.

Photo

News • Immunotherapy effectiveness

Sex differences in pancreatic cancer: researchers reveal possible explanation

For pancreatic cancer, the effect of immunotherapy is limited and differs between men and women. Researchers at Karolinska Institutet have now found a possible explanation for this sex difference.

Related products

Subscribe to Newsletter